Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Genflow Biosciences signs CDAs for dog longevity with animal health groups
MP3•Episode home
Manage episode 506449561 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Genflow Biosciences PLC CEO Dr Eric Leire joined Proactive's Stephen Gunnion with news that the company has signed confidential disclosure agreements (CDAs) with two major animal health companies. Leire explained that these discussions are significant for shareholders as they broaden the company’s market potential, provide possible early cash inflows to reduce capital needs, and validate its scientific platform. “Our core science is focused on tackling ageing and muscle loss. The same approach we use for humans has real potential for companion animals,” Leire said. He noted that the global pet market is expanding, and Genflow’s work in this area could deliver solutions to extend lifespan and improve the quality of life for ageing dogs. He also highlighted that early safety data from the company’s first dog trials have been positive. The administration of the treatment was straightforward, with no signs of discomfort or behavioural change in the animals. Leire said this suggests the product could translate into a commercially viable therapy. The next key milestone will be efficacy data from the dog trials, expected within five months. Leire expressed confidence, citing strong results previously observed in mice studies. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #Biotech #Longevity #AnimalHealth #PetWellness #DrugDevelopment #ClinicalTrials #AgingResearch #LifeSciences #InvestorNews
…
continue reading
606 episodes
MP3•Episode home
Manage episode 506449561 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Genflow Biosciences PLC CEO Dr Eric Leire joined Proactive's Stephen Gunnion with news that the company has signed confidential disclosure agreements (CDAs) with two major animal health companies. Leire explained that these discussions are significant for shareholders as they broaden the company’s market potential, provide possible early cash inflows to reduce capital needs, and validate its scientific platform. “Our core science is focused on tackling ageing and muscle loss. The same approach we use for humans has real potential for companion animals,” Leire said. He noted that the global pet market is expanding, and Genflow’s work in this area could deliver solutions to extend lifespan and improve the quality of life for ageing dogs. He also highlighted that early safety data from the company’s first dog trials have been positive. The administration of the treatment was straightforward, with no signs of discomfort or behavioural change in the animals. Leire said this suggests the product could translate into a commercially viable therapy. The next key milestone will be efficacy data from the dog trials, expected within five months. Leire expressed confidence, citing strong results previously observed in mice studies. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #GenflowBiosciences #Biotech #Longevity #AnimalHealth #PetWellness #DrugDevelopment #ClinicalTrials #AgingResearch #LifeSciences #InvestorNews
…
continue reading
606 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.